GlaxoSmithKline: Requip effective in Parkinson's disease

By Lisa Kerner

Charlotte, N.C., Sept. 5 - GlaxoSmithKline said the addition of its investigational Requip (ropinirole HCl) extended-release tablets to existing Parkinson's disease therapy delayed the time in which symptoms return as medication wears off by an average of 2.1 hours per day compared to the placebo's 0.4 hours.

In the 24-week EASE-PD Adjunct study, patients with Parkinson's disease not controlled with levodopa (L-dopa) were randomized to receive either Requip 24-hour extended release tablets or a placebo once daily for 24 weeks.

The study data was presented Monday at the annual European Federation of Neurological Societies Congress.

The latest formulation of Requip is based on SkyePharma plc's oral controlled release proprietary technology.

GlaxoSmithKline is a London-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.